Middletons acted in the successful capital raising and ASX listing of the international biotechnology company CyGenics Ltd with a market capitalisation of just under $70 million on IPO. CyGenics is a leader in the development and commercialisation of stem cell related technologies and applications covering tissue banking, tissue engineering, cell growth biomanufacturing, biologics and cell therapy. The fund raising through the IPO is to provide for further business expansion and human clinical trials of the technology. Middletons partners Peter Howard and Andrew Gaffney headed the Middletons team in the listing.
Skaddens represented Edison Mission Energy (Edison) and its major domestic subsidiary, Midwest Generation, LLC, in an approximately US$2 ($2.8) billion financing consisting of: a US$900 million first priority secured credit facility; a private offering of US$1 billion 8.75 per cent second priority senior secured notes due 2034; and a US$98 million secured working capital facility. The firm said the financing, which closed on April 27, was implemented using a dual-lien structure, in which the banks in the US$900 million credit facility took a first priority security interest and the bondholders took a second priority security interest in a fleet of power plants and related assets located in Illinois.
Linklaters has advised on what it said was believed to be the largest project financing of ships to date. The limited recourse financing of four LNG vessels for long-term charter to the RasGas II liquefied natural gas project in Qatar has a total value of US $700 ($997) million. The firm advised the group of six mandated lead arrangers: ANZ Investment Bank, BNP Paribas, Crédit Agricole Indosuez, Société Générale, Sumitomo Mitsui Banking Corporation Europe Limited and The Bank of Tokyo-Mitsubishi, Ltd. The Linklaters team was led by projects partner Jeremy Gewirtz, assisted by Christopher Bradley, David Charlier and Dimitri Papaefstratiou.
Like this story? Read more: